CR11079A - Anticuerpos contra il-25 - Google Patents

Anticuerpos contra il-25

Info

Publication number
CR11079A
CR11079A CR11079A CR11079A CR11079A CR 11079 A CR11079 A CR 11079A CR 11079 A CR11079 A CR 11079A CR 11079 A CR11079 A CR 11079A CR 11079 A CR11079 A CR 11079A
Authority
CR
Costa Rica
Prior art keywords
antibodies against
present
antibody
antibodies
domains
Prior art date
Application number
CR11079A
Other languages
English (en)
Inventor
Andrew Neil James Mckenzie
Sarah Ballantyne
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of CR11079A publication Critical patent/CR11079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a anticuerpos, incluyendo fragmentos de union de los mismos, dirigidos contra la interleuquina 25 (IL-25). Las realizaciones preferidas de la presente invencion emplean los dominios VH Y/O VL de anticuerpo de anticuerpo 2C3.
CR11079A 2007-04-18 2009-10-28 Anticuerpos contra il-25 CR11079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91247407P 2007-04-18 2007-04-18
GBGB0707505.4A GB0707505D0 (en) 2007-04-18 2007-04-18 Antibodies against il-25

Publications (1)

Publication Number Publication Date
CR11079A true CR11079A (es) 2010-03-03

Family

ID=38135020

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11079A CR11079A (es) 2007-04-18 2009-10-28 Anticuerpos contra il-25

Country Status (32)

Country Link
US (1) US8206717B2 (es)
EP (1) EP2144934B1 (es)
JP (1) JP5366930B2 (es)
KR (1) KR101605861B1 (es)
CN (1) CN101711256B (es)
AU (1) AU2008240436B2 (es)
BR (1) BRPI0810418A8 (es)
CA (1) CA2684492C (es)
CO (1) CO6260104A2 (es)
CR (1) CR11079A (es)
CY (1) CY1118244T1 (es)
DK (1) DK2144934T3 (es)
EA (1) EA018073B1 (es)
EC (1) ECSP099726A (es)
ES (1) ES2604255T3 (es)
GB (1) GB0707505D0 (es)
GT (1) GT200900271A (es)
HN (1) HN2009003038A (es)
HR (1) HRP20161548T1 (es)
HU (1) HUE030935T2 (es)
IL (1) IL201552A (es)
LT (1) LT2144934T (es)
MX (1) MX2009011234A (es)
MY (1) MY148451A (es)
NI (1) NI200900189A (es)
NZ (1) NZ581178A (es)
PL (1) PL2144934T3 (es)
PT (1) PT2144934T (es)
RS (1) RS55401B1 (es)
SI (1) SI2144934T1 (es)
UA (1) UA100377C2 (es)
WO (1) WO2008129263A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
US8574582B2 (en) * 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
SG184195A1 (en) * 2010-03-30 2012-11-29 Janssen Biotech Inc Humanized il-25 antibodies
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
JP6250351B2 (ja) * 2013-09-30 2017-12-20 シスメックス株式会社 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
SG10201913084PA (en) 2014-09-23 2020-03-30 Regeneron Pharma Anti-il-25 antibodies and uses thereof
KR102477922B1 (ko) * 2016-03-16 2022-12-14 아베오미 코포레이션 Il-25에 대한 중화 모노클로날 항체 및 그의 용도
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
US20210332123A1 (en) * 2018-11-19 2021-10-28 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-il-25 antibodies and use thereof
GB202018015D0 (en) 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CN1289668C (zh) * 2003-06-12 2006-12-13 北京安波特基因工程技术有限公司 一种用于抗体改形的体外分子定向进化方法
EP1863520B1 (en) 2005-03-08 2014-12-31 Aptose Biosciences Inc. Use of interleukin 17e for the treatment of cancer
CA2658833A1 (en) 2005-10-06 2007-04-19 Baylor Research Institute Compositions and methods for the treatment of cancer
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25

Also Published As

Publication number Publication date
RS55401B1 (sr) 2017-04-28
CO6260104A2 (es) 2011-03-22
EA200901421A1 (ru) 2010-10-29
HN2009003038A (es) 2011-11-11
NZ581178A (en) 2012-01-12
ES2604255T3 (es) 2017-03-06
JP5366930B2 (ja) 2013-12-11
DK2144934T3 (en) 2016-12-12
IL201552A0 (en) 2010-05-31
AU2008240436B2 (en) 2011-03-17
IL201552A (en) 2015-08-31
MX2009011234A (es) 2010-02-18
BRPI0810418A8 (pt) 2018-12-11
AU2008240436A1 (en) 2008-10-30
NI200900189A (es) 2010-09-13
EP2144934B1 (en) 2016-08-24
US20100129380A1 (en) 2010-05-27
WO2008129263A1 (en) 2008-10-30
CN101711256B (zh) 2013-10-16
EA018073B1 (ru) 2013-05-30
HUE030935T2 (en) 2017-06-28
PT2144934T (pt) 2016-12-02
HRP20161548T1 (hr) 2016-12-30
CY1118244T1 (el) 2017-06-28
CA2684492C (en) 2015-11-24
KR20100021569A (ko) 2010-02-25
BRPI0810418A2 (pt) 2014-10-14
CN101711256A (zh) 2010-05-19
SI2144934T1 (sl) 2016-12-30
LT2144934T (lt) 2016-12-27
KR101605861B1 (ko) 2016-03-24
UA100377C2 (en) 2012-12-25
MY148451A (en) 2013-04-30
US8206717B2 (en) 2012-06-26
PL2144934T3 (pl) 2017-07-31
CA2684492A1 (en) 2008-10-30
ECSP099726A (es) 2010-01-29
EP2144934A1 (en) 2010-01-20
JP2010524450A (ja) 2010-07-22
GT200900271A (es) 2010-11-03
GB0707505D0 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
CR11079A (es) Anticuerpos contra il-25
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
NO20092652L (no) Konstruert anti-TSLP-antistoff
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
BR112012017051A2 (pt) método para diminuir a imunogenicidade
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EA200802168A1 (ru) Гуманизированное антитело к с-kit
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
EA200800417A1 (ru) Анти-il-23 антитела
CY1116313T1 (el) Αντισωματα εναντιον il-25
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX2010007357A (es) Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular.
WO2010051502A3 (en) Light targeting molecules and uses thereof
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
TW200716174A (en) Anti-MCP-1 antibodies, compositions, methods and uses
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2011004028A3 (en) Tlr3 binding agents
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.